EUVIMEDEUVIMED entdecken
FallberichtStudienprotokollOpen Access · CC BY-NC 4.0

Rituximab in a desensitization protocol as a rescue therapy in severe nephrotic syndrome—a case report

Agata Bukowska, Aleksandra Rymarz iD, Filip Wantoch-Rekowski iD, Beata Bieniaś iD, Jolanta Małyszko iD

Journal of Nephrology · 04.06.2026 · 39 (1) · 188-191

DOI: 10.1093/joneph/aajaf023 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Nephrology, online erschienen am 01.04.2026. Verfasst von Agata Bukowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Rituximab, Nephrotic Syndrome, Nephrosis, Lipoid, Desensitization, Immunologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic nephrotic syndrome is the most common glomerulopathy in children, and minimal change disease (MCD) is the most common histological pattern. First-line treatment involves glucocorticosteroids, but frequent relapses and steroid dependence may lead to steroid-related complications. Rituximab (RTX) is recommended in cases of lack of response or treatment side effects, reducing relapse rates and limiting the need for other medications. The mechanism of RTX involves B-cell depletion through various cytotoxic mechanisms. Its efficacy in nephrotic syndrome (NS) may stem from its influence on cytokines produced by B cells and a further effect on the podocyte cytoskeleton has been postulated. The present case describes a 19-year-old male with NS resulting from MCD, with a frequently relapsing, steroid-dependent, multidrug-resistant disease. He experienced a hypersensitivity reaction to RTX after the third dose, which contraindicated therapy continuation with traditional infusion. Due to the limited therapeutic options, a 12-step RTX desensitization protocol was adopted, allowing for safe administration of subsequent doses, achievement of remission, and gradual discontinuation of glucocorticosteroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabNephrotic SyndromeNephrosis, LipoidDesensitization, ImmunologicImmunologic FactorsDrug HypersensitivityImmunosuppressive AgentsHumansMaleYoung AdultTreatment OutcomeSeverity of Illness IndexGlucocorticoidsRemission InductionRecurrence

Stichwörter der Autor:innen

desensitization protocolminimal change diseasenephrotic syndromerituximab

Substanzen

RituximabGlucocorticoidsImmunologic FactorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
  • Department of Pediatric Nephrology, Medical University of Lublin, Lublin, Poland.

ORCID-Profile: Aleksandra Rymarz, Filip Wantoch-Rekowski, Beata Bieniaś, Jolanta Małyszko

Zitieren

APA

Bukowska, A., Rymarz, A., Wantoch-Rekowski, F., Bieniaś, B., & Małyszko, J. (2026). Rituximab in a desensitization protocol as a rescue therapy in severe nephrotic syndrome—a case report. Journal of Nephrology, 39(1), 188-191. https://doi.org/10.1093/joneph/aajaf023

Vancouver

Bukowska A, Rymarz A, Wantoch-Rekowski F, Bieniaś B, Małyszko J. Rituximab in a desensitization protocol as a rescue therapy in severe nephrotic syndrome—a case report. Journal of Nephrology. 2026;39(1):188-191. doi:10.1093/joneph/aajaf023

BibTeX
@article{Bukowska2026,
  author = {Bukowska, Agata and Rymarz, Aleksandra and Wantoch-Rekowski, Filip and Bieniaś, Beata and Małyszko, Jolanta},
  title = {Rituximab in a desensitization protocol as a rescue therapy in severe nephrotic syndrome—a case report},
  journal = {Journal of Nephrology},
  year = {2026},
  volume = {39},
  number = {1},
  pages = {188--191},
  doi = {10.1093/joneph/aajaf023}
}
Kostenlos starten →